South Korea-based DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting the latter exclusive rights ...

Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that for the first ...

The sequence homology is over 95%; PTM and aggregation prediction reports are also available 100% success rate As quick as 3–4 weeks to offer required humanized antibodies Affinity evaluated by ...

Moreover, as the gene sequence is known, it can be used time and again. “Knowing that your antibody is going to behave the same way years down the line, gives you peace of mind,” Solache adds.

Selecting a therapeutic antibody that will become commercially successful is often a huge gamble, with candidates potentially failing at any stage of development. Those that are rushed through the ...

Lymph nodes contain antibodies that undergo changes to their sequence as they adapt to their immune target, such as a flu virus. As this happens, the content of regulatory T cell (Treg) epitope ...

In the landmark Amgen v. Sanofi case (previously covered here), the Supreme Court affirmed that patent claims drawn to a genus of ...

Monoclonal antibodies are considered the most rapidly growing class of therapeutics. Critical quality attributes such as sequence assessment, charge and size variants must be thoroughly monitored ...

The global antibody discovery market size is anticipated to reach approximately USD 22,570 million by 2034, up from USD 9,570 ...

EpiVax, Inc. announces a new study published in Frontiers in Immunology unveiling the impact of peptides known as "Tregitopes" on antibody maturation ...